Weak Urine Stream: What Causes It and What to Do Next
Weak stream is often BPH, stricture, or nerve issues. Learn the tests used (PSA, uroflow, PVR) and how alpha-blockers can improve flow within weeks.
Weight Gain: When to See a Doctor
Not all weight gain is benign. Learn the medical causes of unexplained weight gain, red-flag symptoms that warrant evaluation, and when pharmacologic treatment may be appropriate.
Weight Loss Drugs: Medications That Cause or Treat Unintended Weight Loss
A clinical guide to FDA-approved medications that treat obesity-related weight loss goals and drugs known to cause unintended weight loss as a side effect, with dosing, trial data, and when to seek evaluation.
Weight Set Point Shift: Drugs That Cause or Treat It
A clinical guide to medications that raise or lower the body's defended weight range, including GLP-1 agonists, antipsychotics, and antidepressants, with trial data, doses, and timelines.
Word Finding Difficulty: What Could Be Causing It
Word finding difficulty can stem from neurological conditions, medications, sleep deprivation, or anxiety. Learn the causes, diagnostic workup, and treatments backed by clinical evidence.
Word Finding Difficulty: Labs, Diagnosis, and Next Steps
A clinical guide to word finding difficulty (anomia), including the lab panels, imaging, and neuropsychological tests used to identify treatable causes and determine next steps.
Word Finding Difficulty: Drugs That Cause or Treat It
A clinical guide to medications linked to word finding difficulty (anomia) and evidence-based pharmacological treatments, with named trials, dosing, and guideline citations.
Yellow Eyes: Drugs That Cause or Treat Jaundice
A clinical guide to scleral icterus (yellow eyes), covering which medications cause drug-induced jaundice, which drugs treat the underlying conditions, diagnosis, and when to seek emergency care.
Yellow Skin: Labs, Causes, and Next Steps
Yellow skin (jaundice) signals elevated bilirubin. Learn which labs to request, what causes jaundice in adults, and the clinical next steps your doctor should take.
Yellow Skin: When to See a Doctor and What Causes Jaundice
Learn when yellow skin requires urgent medical attention, what causes jaundice in adults, how it is diagnosed, and available treatments backed by clinical evidence.
Tadalafil (Generic) Adult Dosing: Complete Guide for Ages 30 to 49
Evidence-based tadalafil dosing guide for adults aged 30-49, covering daily low-dose and on-demand protocols for erectile dysfunction and BPH.
Tadalafil (Generic) Cost vs. Alternatives: A PDE5 Inhibitor Price and Efficacy Comparison
Compare the cost of generic tadalafil against sildenafil, vardenafil, and avanafil. Includes pricing context, clinical efficacy data, and guidance on choosing among PDE5 inhibitors.
How to Safely Stop Tadalafil (Generic): A Clinician-Informed Discontinuation Protocol
Evidence-based guidance on stopping tadalafil 2.5-20 mg safely, including when tapering matters, what symptoms to expect, and how to manage the return of ED or BPH symptoms after discontinuation.
Tadalafil (Generic) Complete Drug-Drug Interaction Profile
A practical guide to clinically significant tadalafil drug interactions, from absolute contraindications with nitrates to CYP3A4-mediated dosing cautions, organized by what a prescriber or patient actually needs to decide.
Tadalafil (Generic) Food and Supplement Interactions
Evidence-based guide to tadalafil food and supplement interactions, including grapefruit, alcohol, L-arginine, St. John's Wort, and CYP3A4 pathways, with sourcing limits clearly marked.
Tadalafil (Generic): Future Formulations and Pipeline Developments
A clinical review of emerging tadalafil formulations, novel delivery systems, combination therapies, and pipeline developments beyond the standard 2.5-20 mg oral tablet.
Tadalafil (Generic) Manufacturing, Supply & Shortage History
A clinical review of generic tadalafil's manufacturing base, FDA supply chain data, and documented shortage episodes from patent expiry through 2026.
Tadalafil (Generic) Overdose and Accidental Excess Dose: Clinical Management
Evidence-based guide to tadalafil overdose recognition, pharmacokinetics at supratherapeutic doses, and supportive management. Covers accidental double-dosing, intentional excess, and when to seek emergency care.
Tadalafil (Generic) Pediatric Dosing: What Clinicians Need to Know About Use in Children Under 12
Tadalafil has no FDA-approved pediatric indication for children under 12. This evidence review covers off-label dosing research in pulmonary arterial hypertension, safety data, and monitoring requirements for prescribing clinicians.
Tadalafil (Generic) Pediatric Monitoring: What Clinicians Track in Children Under 12
Evidence-based guide to monitoring tadalafil in pediatric patients under 12, covering off-label PAH use, weight-based dosing, hepatic surveillance, hemodynamic tracking, and growth assessment.
Tadalafil (Generic) and Self-Injection Technique: When Oral Therapy Ends and ICI Begins
Tadalafil is an oral PDE5 inhibitor for ED and BPH. Learn how it works, when it fails, and how intracavernosal injection (ICI) therapy serves as the evidence-based next step, including full self-injection technique.
Tadalafil (Generic) in Special Populations: Transplant, HIV, CKD, and Beyond
Evidence-based guide to prescribing generic tadalafil in transplant recipients, HIV-positive patients, chronic kidney disease, hepatic impairment, spinal cord injury, diabetes, and post-prostatectomy populations.
TB-500 Mechanism of Action: Full Pathway From Actin Binding to Tissue Repair
A physician-level explanation of how TB-500 (thymosin beta-4 active fragment) works, covering G-actin sequestration, cell migration signaling, anti-inflammatory cascades, and angiogenic pathways with cited primary sources.
TB-500 Patent Field & Generic Timeline: What Clinicians and Patients Need to Know
A clinical deep-dive into the TB-500 (thymosin beta-4 active fragment) patent field, regulatory status, compounding pharmacy access, and projected generic timeline with cited evidence.
TB-500 Pediatric Safety: What Parents and Clinicians Need to Know About Thymosin Beta-4 in Children Under 12
TB-500 (thymosin beta-4 active fragment) has no FDA-approved indication in any age group and no published pediatric clinical trial data. This article reviews what preclinical and adult evidence actually shows, where the evidence runs out, and what that means for a child under 12.
TB-500 (Thymosin Beta-4 Fragment) During Pregnancy and Lactation: What the Evidence Shows
TB-500 has no human pregnancy or lactation safety data. Learn what animal studies, FDA classification gaps, and clinical pharmacology tell us about thymosin beta-4 fragment risk during pregnancy and breastfeeding.
TB-500 Real-World Evidence: What Registries and RWE Actually Show
A clinical review of real-world evidence for TB-500 (thymosin beta-4 active fragment), including registry data, observational studies, and the gap between animal models and human outcomes.
Egrifta (Tesamorelin) Adult Dosing for Ages 30 to 49: Complete Clinical Guide
Evidence-based tesamorelin (Egrifta) dosing guide for adults aged 30 to 49, covering standard 2 mg subcutaneous injection protocols, administration technique, monitoring, and dose adjustments.
Egrifta (Tesamorelin) Dosing in Hepatic Impairment
Clinical guidance on tesamorelin (Egrifta SV) dosing for patients with hepatic impairment, including pharmacokinetic data, liver safety monitoring, and prescribing considerations for HIV-associated lipodystrophy.
Egrifta (Tesamorelin) Manufacturing, Supply & Shortage History
A clinical review of tesamorelin (Egrifta) manufacturing by Theratechnologies, its pharmaceutical supply chain, FDA shortage listings, and the evolution from multi-vial to single-vial formulation.
Egrifta (Tesamorelin) Missed-Dose Protocol
What to do if you miss a dose of tesamorelin (Egrifta SV), how the drug's pharmacology shapes that guidance, and when a pattern of missed doses needs a prescriber conversation.
Egrifta (Tesamorelin) Pediatric (Under 12) Dosing
Tesamorelin (Egrifta) has no FDA-approved pediatric dosing for children under 12. Review the clinical evidence gaps, safety considerations, and what guidelines say about GHRH analog use in this age group.
Egrifta (Tesamorelin) Pediatric Safety: What Parents and Clinicians Need to Know About Use in Children Under 12
Tesamorelin (Egrifta) is not FDA-approved for pediatric use. This evidence-based review covers safety concerns, off-label considerations, growth hormone axis effects, and clinical guidance for children under 12.
Egrifta (Tesamorelin) Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination
A clinical-depth review of tesamorelin (Egrifta) pharmacokinetics covering absorption after subcutaneous injection, distribution, proteolytic metabolism, and elimination half-life, with FDA label and PubMed-cited evidence.
Egrifta (Tesamorelin) Pregnancy & Lactation Safety
Is tesamorelin (Egrifta) safe during pregnancy or breastfeeding? Evidence-based review of FDA labeling, animal data, GH-axis effects, and clinical guidance for women of childbearing potential.
Egrifta (Tesamorelin) Real-World Evidence: What Registries and RWE Studies Actually Show
A clinical review of tesamorelin (Egrifta) real-world evidence from registries, observational cohorts, and post-marketing studies in HIV-associated lipodystrophy and beyond.
Egrifta (Tesamorelin) Regulatory Status: US, EU, Canada, UK
A comprehensive clinical review of tesamorelin (Egrifta) regulatory approvals, rejections, and compounding status across the US, EU, Canada, and UK, with trial evidence and prescribing context.
Egrifta (Tesamorelin) Self-Injection Technique: Step-by-Step Clinical Guide
Learn the correct tesamorelin (Egrifta SV) self-injection technique, including reconstitution, site selection, rotation, and troubleshooting. prepared by the HealthRX.com Editorial Team.
Tesamorelin (Egrifta) Monitoring for Young Adults (18 to 29): Labs, Timelines, and Clinical Benchmarks
Evidence-based monitoring guide for tesamorelin (Egrifta) in young adults aged 18 to 29 with HIV-associated lipodystrophy. Covers baseline labs, follow-up intervals, IGF-1 tracking, metabolic panels, imaging, and fertility considerations.
Testosterone Cypionate Adolescent (12 to 17) Dosing: Evidence-Based Protocols and Monitoring
Clinical guide to testosterone cypionate dosing in adolescents aged 12 to 17, covering delayed puberty, hypogonadism, and gender-affirming protocols with dose ranges, titration schedules, and safety monitoring.
Testosterone Cypionate Safety in Adults (30 to 49): What the Evidence Shows
A clinical review of testosterone cypionate safety for adults aged 30 to 49, covering cardiovascular risk, hematocrit monitoring, fertility effects, liver considerations, and long-term data from major trials.
Testosterone Cypionate Geriatric (65+) Dosing: Safe Starting Doses, Monitoring, and Adjustment
Evidence-based guide to testosterone cypionate dosing in men 65 and older, covering safe starting doses, monitoring protocols, cardiovascular considerations, and when to adjust or stop therapy.
When Did Testosterone Become a Controlled Substance?
Testosterone became a Schedule III controlled substance in 1990. See testosterone cypionate's 1951 synthesis, 1979 FDA approval, and dosing history.
Does Humana Cover Testosterone Cypionate?
Find out whether Humana covers testosterone cypionate for hypogonadism, including formulary tier, prior authorization requirements, step therapy rules, and how to appeal a denial.
Does State Medicaid Cover Testosterone Cypionate?
State Medicaid coverage for testosterone cypionate varies widely. Learn formulary tiers, prior authorization criteria, step therapy rules, and how to appeal a denial.
Does Medicare Advantage Cover Testosterone Cypionate?
Medicare Advantage plans generally cover testosterone cypionate for diagnosed male hypogonadism under Part D formularies, but prior authorization and step therapy requirements vary by carrier.
Testosterone Cypionate Pediatric (Under 12) Safety: What Clinicians and Parents Need to Know
Evidence-based review of testosterone cypionate safety in children under 12, including FDA labeling, weight-based dosing, bone age monitoring, and growth plate risks.
Testosterone Cypionate in Special Populations: Transplant, HIV, Chronic Disease, and Beyond
Evidence-based guide to testosterone cypionate use in special populations including organ transplant recipients, people living with HIV, opioid-induced hypogonadism, and chronic kidney disease. Dosing, monitoring, and safety data from primary sources.
Testosterone Enanthate Dosing for Adults (30 to 49): Protocols, Monitoring, and Adjustment
Evidence-based testosterone enanthate dosing guide for adults aged 30 to 49 with confirmed hypogonadism. Covers starting doses, titration, injection frequency, lab targets, and when to adjust.
Does Cigna Cover Testosterone Enanthate? Prior Authorization, Formulary Tier, and Appeal Steps
Find out whether Cigna covers testosterone enanthate for hypogonadism, what prior authorization criteria apply, which formulary tier it sits on, and how to appeal a denial.
Testosterone Enanthate Drug-Drug Interactions: Complete Clinical Profile
A guide to every clinically significant drug interaction with testosterone enanthate, including anticoagulants, insulin, corticosteroids, and CYP450-mediated conflicts.
Testosterone Enanthate for Male Hypogonadism: Evidence, Dosing, and What to Expect
Testosterone enanthate is an FDA-approved intramuscular injection for male hypogonadism. Learn about clinical evidence from the T-Trials, standard dosing protocols, side effects, and monitoring requirements.
Testosterone Enanthate Geriatric (65+) Dosing: Safe Protocols, Monitoring, and Adjustments
Evidence-based guide to testosterone enanthate dosing in men 65 and older, covering starting doses, titration, cardiovascular monitoring, and when to adjust or stop therapy.
Testosterone Enanthate Geriatric (65+) Monitoring: Lab Schedules, Safety Thresholds, and Clinical Protocols
Evidence-based monitoring guide for testosterone enanthate in men 65 and older, covering lab timing, hematocrit thresholds, cardiovascular screening, bone density tracking, and deprescribing criteria.
Testosterone Enanthate Dosing in Hepatic Impairment
Evidence-based guide to testosterone enanthate dose adjustment in liver disease, covering pharmacokinetics, monitoring, and safety in mild, moderate, and severe hepatic impairment.
Does Humana Cover Testosterone Enanthate? Prior Authorization, Formulary Tier, and Appeal Steps
Find out whether Humana covers testosterone enanthate for hypogonadism, what prior authorization criteria apply, which formulary tier it sits on, and how to appeal a denial.
TRT Monitoring Schedule: How Often You Need Labs & Checkups
Baseline labs, then follow-up at 6 to 12 weeks, then every 6 to 12 months once stable. See what tests are checked and target trough levels.
Testosterone Enanthate Off-Label Uses with Evidence Levels
A clinician-grade review of testosterone enanthate off-label applications, from female hypoactive sexual desire disorder to HIV-associated wasting, organized by strength of evidence and monitoring burden.
Testosterone Enanthate Overdose and Accidental Excess Dose: Recognition, Risks, and Clinical Management
What happens if you take too much testosterone enanthate? A guide covering overdose symptoms, acute management, long-term risks of supraphysiologic dosing, and when to seek emergency care.
Testosterone Enanthate Pharmacokinetics (ADME)
A clinical breakdown of testosterone enanthate absorption, distribution, metabolism, and excretion, with half-life data, peak serum timing, and dosing implications.